AngioDynamics
ANGO
144 hedge funds and large institutions have $769M invested in AngioDynamics in 2022 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 49 increasing their positions, 71 reducing their positions, and 35 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
3.07% more ownership
Funds ownership: 93.93% → 97% (+3.1%)
15% less funds holding
Funds holding: 170 → 144 (-26)
18% less capital invested
Capital invested by funds: $941M → $769M (-$172M)
31% less repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 71
71% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 35
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $218K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
+$14.1M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$13.7M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$11.6M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$8.33M |
| 5 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$7.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$5.98M |
| 2 |
Millennium Management
New York
|
-$5.62M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$5.5M |
| 4 |
Goldman Sachs
New York
|
-$4.84M |
| 5 |
CCM
Cinctive Capital Management
New York
|
-$4.66M |
ANGO Hedge Fund Activity: Q1 2022 in Review
144 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in AngioDynamics (ANGO) for Q1 2022, worth a combined $769M — down 18% from $941M a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of ANGO and 10 opened new positions — a net loss of 25 holders — while 71 trimmed existing stakes and 49 added.
The largest buyer was Victory Capital Management, adding an estimated $14.1M. The largest seller was Arrowstreet Capital, exiting entirely with an estimated $5.98M sold.
- 144 institutional investors held AngioDynamics (ANGO) as of Q1 2022, down from 170 in Q4 2021.
- Funds reported $769M of AngioDynamics stock for Q1 2022, down 18% quarter-over-quarter.
- 10 funds opened new AngioDynamics positions in Q1 2022 and 35 closed out, a net change of -25 holders.
- The largest AngioDynamics buyer in Q1 2022 was Victory Capital Management, an estimated $14.1M added.
- The largest AngioDynamics seller in Q1 2022 was Arrowstreet Capital, an estimated $5.98M sold.
Based on aggregated 13F filings for Q1 2022.